Maybe this is why some people report GI distress when they start dosing from t-resveratrol (read the 1st two sentences of the abstract). They claimed to have synthesized this in multigram quantities, perhaps it will be available soon. At least the 3,5 dihydroxy form should be more water soluble.
It's from a reputable journal, I don't have access to the full article yet, however.
J Pharmacol Exp Ther. 2008 Dec 9. [Epub ahead of print]
Improved Anti-ulcer and Anticancer Properties of a trans-Resveratrol Analog in Mice.
Guha P, Dey A, Sarkar B, Dhyani MV, Chattopadhyay S, Bandyopadhyay SK.
Dr. B.C. Roy Post Graduate Institute of Basic medical Sciences & IPGME&R, Kolkata, India.
In spite of its potential, use of trans-resveratrol as an anti-cancer drug is severely constrained due to its tendency to prolong gastric ulceration. We found that besides delaying ulcer healing, trans-resveratrol also aggravated acute gastric ulceration-induced by the non-steroidal anti-inflammatory drugs (NSAIDs) by reducing the synthesis of prostaglandin (PG)E2 via a specific inhibition of cyclooxygenase-1 (COX-1) that also hampered angiogenesis. However, for the first time we showed that 3'-5'-hydroxylated congener [(E)-HST-1] of trans-resveratrol, synthesized in multigram scale exerted potential chemotherapeutic property but was non-ulcerogenic in nature, rather moderately accelerated healing of indomethacin-induced gastric ulceration. HST-1 did not suppress COX-1, COX-2 expression and (PG)E2 synthesis, but reduced the level of inflammatory myeloperoxidase (MPO) activity. Healing augmented primarily through nitric oxide synthase (NOS) dependent pathway. HST-1 treatment induced endothelial NOS (eNOS) expression and reduced inducible NOS (iNOS) resulting in increased eNOS/iNOS ratio. Selective iNOS inhibitor (L-NIL) and nonselective NOS inhibitor (L-NAME) treatment revealed that eNOS could be the probable molecular switch to accelerate the indomethacin induced ulcer healing in HST-1 treated mice. Further, the anticancer effect of HST-1 on U937 and K562 leukemia cell lines was found to be significantly better than that of trans-resveratrol. Overall, these established HST-1 as a potentially better anti-cancer compound than trans-resveratrol considering it is devoid of any ulcerogenic side effects. In conclusion, for the first time we showed that a novel analog of trans-resveratrol, HST-1 was devoid of ulcerogenic adversative effects of trans-resveratrol but retained potentially better anticancer property.
PMID: 19066340